The Possible Mechanism and Research Progress of ACE2 Involved in Cardiovascular Injury Caused by COVID-19: a Review

Overview

Journal Front Cardiovasc Med

Specialty Cardiology & Vascular Diseases

Date 2024 Jun 12

PMID 38863899

Authors

Dan Luo

Mengzhe Bai

Wei Zhang

Junnan Wang

Affiliations

Soon will be listed here.

Abstract

ACE2 is the earliest receptor discovered to mediate the entry of SARS-CoV-2. In addition to the receptor, it also participates in complex pathological and physiological processes, including regulating the RAS system, apelin, KKS system, and immune system. In addition to affecting the respiratory system, viral infections also interact with cardiovascular diseases. SARS-CoV-2 can directly invade the cardiovascular system through ACE2; Similarly, cardiovascular diseases such as hypertension and coronary heart disease can affect ACE2 levels and exacerbate the disease, and ACE2 dysregulation may also be a potential mechanism for long-term acute sequelae of COVID-19. Since the SARS CoV-2 epidemic, many large population studies have tried to clarify the current focus of debate, that is, whether we should give COVID-19 patients ACEI and ARB drug treatment, but there is still no conclusive conclusion. We also discussed potential disease treatment options for ACE2 at present. Finally, we discussed the researchers' latest findings on ACE2 and their prospects for future research.

References

Sama I, Ravera A, Santema B, Goor H, Ter Maaten J, Cleland J . Circulating plasma concentrations of angiotensin-converting enzyme 2 in men and women with heart failure and effects of renin-angiotensin-aldosterone inhibitors. Eur Heart J. 2020; 41(19):1810-1817. PMC: 7239195. DOI: 10.1093/eurheartj/ehaa373. View

Lawler P, Derde L, van de Veerdonk F, McVerry B, Huang D, Berry L . Effect of Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Initiation on Organ Support-Free Days in Patients Hospitalized With COVID-19: A Randomized Clinical Trial. JAMA. 2023; 329(14):1183-1196. PMC: 10326520. DOI: 10.1001/jama.2023.4480. View

Mughal A, ORourke S . Vascular effects of apelin: Mechanisms and therapeutic potential. Pharmacol Ther. 2018; 190:139-147. PMC: 6165679. DOI: 10.1016/j.pharmthera.2018.05.013. View

Inciardi R, Lupi L, Zaccone G, Italia L, Raffo M, Tomasoni D . Cardiac Involvement in a Patient With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020; 5(7):819-824. PMC: 7364333. DOI: 10.1001/jamacardio.2020.1096. View

Burrell L, Risvanis J, Kubota E, Dean R, Macdonald P, Lu S . Myocardial infarction increases ACE2 expression in rat and humans. Eur Heart J. 2005; 26(4):369-75. DOI: 10.1093/eurheartj/ehi114. View

Jia H . Pulmonary Angiotensin-Converting Enzyme 2 (ACE2) and Inflammatory Lung Disease. Shock. 2016; 46(3):239-48. DOI: 10.1097/SHK.0000000000000633. View

Cooper S, Boyle E, Jefferson S, Heslop C, Mohan P, Mohanraj G . Role of the Renin-Angiotensin-Aldosterone and Kinin-Kallikrein Systems in the Cardiovascular Complications of COVID-19 and Long COVID. Int J Mol Sci. 2021; 22(15). PMC: 8347967. DOI: 10.3390/ijms22158255. View

Brevini T, Maes M, Webb G, John B, Fuchs C, Buescher G . FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2. Nature. 2022; 615(7950):134-142. PMC: 9977684. DOI: 10.1038/s41586-022-05594-0. View

Reynolds H, Adhikari S, Pulgarin C, Troxel A, Iturrate E, Johnson S . Renin-Angiotensin-Aldosterone System Inhibitors and Risk of Covid-19. N Engl J Med. 2020; 382(25):2441-2448. PMC: 7206932. DOI: 10.1056/NEJMoa2008975. View

10.

Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong J, Turner A . Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circ Res. 2020; 126(10):1456-1474. PMC: 7188049. DOI: 10.1161/CIRCRESAHA.120.317015. View

11.

Gue Y, Gorog D . Reduction in ACE2 may mediate the prothrombotic phenotype in COVID-19. Eur Heart J. 2020; 41(33):3198-3199. PMC: 7454491. DOI: 10.1093/eurheartj/ehaa534. View

12.

Fraga-Silva R, Sorg B, Wankhede M, DeDeugd C, Jun J, Baker M . ACE2 activation promotes antithrombotic activity. Mol Med. 2010; 16(5-6):210-5. PMC: 2811560. DOI: 10.2119/molmed.2009.00160. View

13.

Puntmann V, Carerj M, Wieters I, Fahim M, Arendt C, Hoffmann J . Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020; 5(11):1265-1273. PMC: 7385689. DOI: 10.1001/jamacardio.2020.3557. View

14.

Ocaranza M, Riquelme J, Garcia L, Jalil J, Chiong M, Santos R . Counter-regulatory renin-angiotensin system in cardiovascular disease. Nat Rev Cardiol. 2019; 17(2):116-129. PMC: 7097090. DOI: 10.1038/s41569-019-0244-8. View

15.

Lambert D, Yarski M, Warner F, Thornhill P, Parkin E, Smith A . Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2). J Biol Chem. 2005; 280(34):30113-9. PMC: 8062222. DOI: 10.1074/jbc.M505111200. View

16.

Tregoning J, Flight K, Higham S, Wang Z, Pierce B . Progress of the COVID-19 vaccine effort: viruses, vaccines and variants versus efficacy, effectiveness and escape. Nat Rev Immunol. 2021; 21(10):626-636. PMC: 8351583. DOI: 10.1038/s41577-021-00592-1. View

17.

Turner A, Nalivaeva N . Angiotensin-converting enzyme 2 (ACE2): Two decades of revelations and re-evaluation. Peptides. 2022; 151:170766. PMC: 8830188. DOI: 10.1016/j.peptides.2022.170766. View

18.

Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View

19.

Vallance P, Collier J, Bhagat K . Infection, inflammation, and infarction: does acute endothelial dysfunction provide a link?. Lancet. 1997; 349(9062):1391-2. DOI: 10.1016/S0140-6736(96)09424-X. View

20.

Varga Z, Flammer A, Steiger P, Haberecker M, Andermatt R, Zinkernagel A . Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020; 395(10234):1417-1418. PMC: 7172722. DOI: 10.1016/S0140-6736(20)30937-5. View